SBIR Phase I: Blockchain Platform for the Secure Distribution of Medicine

SBIR 第一阶段：药品安全配送的区块链平台

• 批准号: 1940394
• 负责人: Joshua Ogrey
• 金额: $ 22.5万
• 依托单位: QCMEDCHAIN LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1940394&HistoricalAwards=false
• 关键词: SBIR; Phase; Blockchain; Platform; Secure

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to empower trading partners and key stakeholders in the pharmaceutical supply chain with the ability to track provenance, authenticate medicines, perform targeted recalls, and implement item-level serialization and aggregation on a cost-effective basis. Currently, the pharmaceutical supply chain is plagued by outdated legacy systems, expensive/inefficient product recalls, and counterfeit drugs. The consumption of counterfeit and substandard medicines claims over a million lives annually, while diverting between $75 – $200 Billion in sales from the legitimate pharmaceutical industry. Today, counterfeiters succeed due to a lack of transparency and security throughout the supply chain. With counterfeiters’ rapid adaption to anti-counterfeiting technology, this research aims to develop a platform that enables enterprises to reclaim their revenues and consumer trust with end-to-end visibility through the utilization of blockchain technology. This SBIR Phase I project proposes to develop a secure, scalable, enterprise-grade blockchain platform designed to advance the traceability of medicine within the pharmaceutical supply chain. The project aims to significantly progress the state of the art in serialization and aggregation, secure/efficient data transmission between trading partners, and anti-counterfeiting technology. To accomplish these ends, this project will consist of the design and implementation of proprietary technology consisting of cutting-edge cryptographic algorithms, blockchain architectures, and smart contract protocols to prove technical feasibility within the SBIR Phase I research timeline. This research also aims to establish commercial viability of the innovation by testing transaction scalability, smart contract security, and data privacy on the blockchain network. This project will test scalability by simulating billions of serialized events on the network and benchmarking the blockchain architectures that significantly exceed the current state of the art in serialization and track & trace software. The project intends to explore the viability of smart contracts for automating the verification of transactions and products moving through the supply chain. Since the security of these smart contracts is critical to authentic product/transaction verification, the smart contracts will be tested against adversarial cybersecurity threats and scenarios with unauthorized user access. This project intends to considerably increase data privacy within blockchain networks in order to allow users of the platform the ability to safeguard trade secrets and proprietary knowledge contained within transaction data.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）项目的更广泛的影响/商业潜力是赋予药品供应链中的贸易伙伴和主要利益相关者追踪来源、鉴定药品、执行有针对性的召回以及在具有成本效益的基础上实施项目级序列化和汇总的能力。目前，药品供应链受到过时的遗留系统、昂贵/低效的产品召回和假药的困扰。假药和不合格药品的消费每年夺去100多万人的生命，同时从合法制药业转移了750亿至2000亿美元的销售额。今天，由于整个供应链缺乏透明度和安全性，造假者得以成功。随着造假者对防伪技术的快速适应，本研究旨在开发一个平台，通过利用区块链技术，使企业能够通过端到端可见性收回其收入和消费者信任。SBIR第一阶段项目建议开发一个安全的、可扩展的、企业级区块链平台，旨在提高药品供应链中药品的可追溯性。该项目的目的是在序列化和聚合、贸易伙伴之间安全/有效的数据传输和防伪技术方面取得重大进展。为了实现这些目标，该项目将包括设计和实施由尖端加密算法、区块链架构和智能合约协议组成的专有技术，以证明在SBIR第一阶段研究时间表内的技术可行性。本研究还旨在通过测试区块链网络上的交易可扩展性，智能合约安全性和数据隐私来确定创新的商业可行性。该项目将通过模拟网络上数十亿个序列化事件来测试可伸缩性，并对区块链架构进行基准测试，区块链架构在序列化和跟踪跟踪软件方面明显超过了当前的技术水平。该项目旨在探索智能合约在供应链中自动验证交易和产品的可行性。由于这些智能合约的安全性对于真实的产品/交易验证至关重要，因此智能合约将针对对抗性网络安全威胁和未经授权用户访问的场景进行测试。该项目旨在大幅提高b区块链网络中的数据隐私性，以便平台用户能够保护交易数据中包含的商业秘密和专有知识。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。